

1 October 2026

Execution of Loan Facility Agreement

Argent BioPharma Ltd (**Argent** or the **Company**) is pleased to advise it has entered into two loan facility agreements (together, the **Loan Facility**) with WVP Emerging Manager Onshore Fund LLC – C/M Capital Series and C/M Capital Master Fund, LP, (together, the **Lenders**). Each Lender has agreed to provide a funding facility of up to US\$250,000, being US\$500,000 in aggregate. Proceeds will be used for the Company's working capital requirements, covering corporate costs and research and development activities.

Key Terms:

- US\$250,000 limit per facility, each a non-revolving cash advance facility with a single drawdown;
- Each facility is subject to a 9-month repayment term after drawdown (or on another date agreed in writing);
- Repayment amount: US\$287,500 per facility with no ongoing interest charges;
- The Loan Facilities are unsecured;
- Default interest: 18% per annum on overdue amounts; and
- If the Company completes a capital raise of at least A\$5.0 million from third parties (excluding funds advanced under the Convertible Securities Agreements), each Lender may require repayment within 15 business days of written notice;

Each Lender is a counterparty to a convertible securities agreement with the Company. In connection with the Loan Facilities, each Lender has consented to the Company incurring this indebtedness and has waived its rights under the relevant provisions of those agreements in respect of it. The Lenders are not related parties or substantial holders of the Company.

This announcement has been authorised for release by the Board of Directors of Argent Biopharma Limited.

— Ends —

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer
Chairman

+61 8 6555 2950


info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary

+61 8 6555 2950

info@argentbiopharma.com



About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated immune-modulation intellectual property platform through the development, commercialisation and strategic licensing of innovative therapeutics. The Company's portfolio is anchored by CimetrA®, a first-in-class immune-modulating platform targeting inflammatory and autoimmune diseases, supported by proprietary NanoBodies™ and peptide technologies, advanced nano-delivery systems and EU-GMP manufacturing capabilities. Following the global licensing of CannEpil®, Argent BioPharma has adopted a capital-efficient strategy that combines proprietary intellectual property, commercial-stage products, strategic licensing, manufacturing services and recurring royalty income to create long-term shareholder value. With a focused pipeline of immune-modulating technologies, a growing portfolio of proprietary pharmaceutical assets and an expanding commercial platform, Argent BioPharma is positioning itself as a next-generation specialty pharmaceutical company with a clear pathway toward expansion into the United States capital markets.



Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com